Clinical Trials Logo

Clinical Trial Summary

To derive the maximum tolerated dose of hypofractionated stereotactic body radiotherapy (SBRT) using dose painting by numbers with immunomodulating systemic therapy in patients that are reirradiated for recurrent squamous cell carcinoma of the head and neck.


Clinical Trial Description

The standard treatment in inoperable locally or regionally recurrent head and neck cancer has long been palliative systemic therapy using the so-called EXTREME-scheme: a combination of cisplatin, 5-fluorouracil and cetuximab. This therapy remains without realistic chances of cure. More recently, immunotherapy using nivolumab has demonstrated to result in long-term disease control of 1-2 year in cisplatin-refractory recurrent or metastatic head and neck cancer, however only in a small portion of patients (13%). Fractionated high-dose local or regional re-irradiation is mostly given in a 6-7 weeks scheme. Using stereotactic body radiotherapy (SBRT), high radiotherapy doses can be given in a short time span. Severe late adverse events have been reported using SBRT but seem less frequent than in patients re-treated with conventional schedules. A possible solution to be able to administer higher doses is combining SBRT with dose painting, thus giving these high doses on small subvolumes only. Addition of concomitant therapy to reirradiation may further improve outcomes due to radiosensitization and direct cytotoxicity. Therefore the investigator aims to combine high doses with concomitant therapy in the proposed study. The immunomodulatory effect caused by radiation has been demonstrated both in animal models and clinical trials and leads to an enhanced local control as well as to eradication of distant metastasis. This so-called abscopal effect is reached through a systemic immune response evoked by the release of damage-associated molecular patterns (DAMPs) by the dying tumor-cells, also called immunogenic cell death (ICD). The investigator hypothesizes that an abscopal effect could be present for patients presenting locoregional recurrent disease with asymptomatic distant metastases, thereby offering at least symptom control at the primary site while palliative systemic treatment could be postponed. The proposed protocol focuses on patients with bad prognosis, as determined by a short timespan between primary therapy and recurrence (defined as 6-24 months after the end of the primary radiotherapy). It would bring the practical advantage of only 2-3 patient visits for the radiotherapy instead of ± 30-35 visits over 6-7 weeks. This shorter treatment schedule is expected to result in a direct gain in quality-of-life due to locoregional symptom control. It can also be expected that rescue systemic therapy will be postponed to a later stage of disease development, thereby prolonging overall survival. The combination with systemic agents that are involved in immunogenic cell death bear the potential to result in a higher number of patients with longer periods of disease control and survival. The current standard of care, i.e. the combined systemic treatment with cisplatin - 5-fluorouracil - cetuximab, or nivolumab in case of former cisplatin use, can be used as a rescue regimen in case of therapy failure. In that sense, better overall survival from time of diagnosis of the index locoregional recurrent disease is expected. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03402737
Study type Interventional
Source University Hospital, Ghent
Contact
Status Terminated
Phase N/A
Start date July 31, 2017
Completion date December 3, 2020

See also
  Status Clinical Trial Phase
Completed NCT02960308 - Whole-Neck Computed Tomography Perfusion Scan in Imaging Patients With Head and Neck Tumors
Terminated NCT02602067 - 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients Phase 1
Completed NCT04277273 - Characteristics of a Maxillofacial Prosthesis Consultation Within Assistance Publique - Hopitaux de Paris N/A
Completed NCT03896906 - Preoxygenation With a High-flow Nasal Cannula or a Simple Mask Before General Anesthesia in Head and Neck Surgery N/A
Completed NCT01621295 - Assessing the Patient Experience in Cancer Care N/A
Active, not recruiting NCT03854838 - IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. Phase 2
Completed NCT04151030 - Endoscopic Direct-PEG Placement in Patients Unable to Undergo Pull-PEG Procedure N/A
Completed NCT03012581 - Secured Access to Nivolumab for Adult Patients With Selected Rare Cancer Types Phase 2
Active, not recruiting NCT04005521 - Randomized Study Regarding Preventive Jaw- and Swallowing Intervention for Patients With Head and Neck Cancer N/A
Recruiting NCT05011500 - Masks Against Surface-Scanning for Radiation Therapy Immobilisation in Head and Neck Cancer (MASSC) N/A
Completed NCT05590650 - A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients Phase 1
Completed NCT04086849 - Analysis of Patterns of Recurrence in Head and Neck Cancer Using Clinicopathomic Markers
Completed NCT00001442 - A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer Phase 1
Recruiting NCT04477759 - Dose-Escalated Hypofractionated Adaptive Radiotherapy for Head and Neck Cancer Phase 1
Terminated NCT00423150 - Phase 2 Study of Temozolomide in Pre-Selected Advanced Aerodigestive Tract Cancers (Study P04273AM2)(TERMINATED) Phase 2
Recruiting NCT03757091 - Flexible Intubation Scope With or Without Video Laryngoscope in Supporting Endotracheal Tube Placement in Patients With Head and Neck Cancer Before Surgery N/A
Recruiting NCT04099290 - Circulating Tumor DNA (ctDNA) in Locally Advanced Head and Neck Squamous Cell Carcinoma
Withdrawn NCT04679233 - Feasibility and Safety of Aerobic Exercise for Head and Neck Cancer Patients N/A
Not yet recruiting NCT04267627 - Telemedicine Nurse-Led Intervention for Rural Cancer Survivors N/A
Completed NCT00666926 - Study Of PF-00562271, Including Patients With Pancreatic, Head And Neck, Prostatic Neoplasms Phase 1